This tool would enable the calculation of an individual patient's likelihood of prostate cancer positivity by incorporating various clinical parameters, such as PSA level, PI‐RADS, prostate size, age, PHI, and [−2]proPSA/%f‐PSA, which was better than PHI in terms of AUC –ROC for patients diagnosed with csPC. This evidence concerns the gene KLK3 and prostate cancer.